MX2007001292A - Metodo para modular la expresion genica al alterar el contendido de cpg. - Google Patents
Metodo para modular la expresion genica al alterar el contendido de cpg.Info
- Publication number
- MX2007001292A MX2007001292A MX2007001292A MX2007001292A MX2007001292A MX 2007001292 A MX2007001292 A MX 2007001292A MX 2007001292 A MX2007001292 A MX 2007001292A MX 2007001292 A MX2007001292 A MX 2007001292A MX 2007001292 A MX2007001292 A MX 2007001292A
- Authority
- MX
- Mexico
- Prior art keywords
- modifying
- gene expression
- modulating gene
- cpg content
- relates
- Prior art date
Links
- 230000014509 gene expression Effects 0.000 title abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 239000013604 expression vector Chemical class 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/46—Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Electrotherapy Devices (AREA)
- Control Of Electric Motors In General (AREA)
- Oscillators With Electromechanical Resonators (AREA)
Abstract
La invencion se refiere a modificaciones de acido nucleico para una modulacion de expresion dirigida por la insercion o remocion dirigida de dinucleotidos de CpG. La invencio tambien se refiere a acidos nucleidos modificados y vectores de expresion modificados.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004037611A DE102004037611B4 (de) | 2004-08-03 | 2004-08-03 | Induzierbare Genexpression |
DE200410037652 DE102004037652B4 (de) | 2004-08-03 | 2004-08-03 | Verfahren zur Modulation der Genexpression durch Änderung des CpG Gehalts |
PCT/EP2005/008423 WO2006015789A2 (de) | 2004-08-03 | 2005-08-03 | Verfahren zur modulation der genexpression durch änderung des cpg gehalts |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2007001292A true MX2007001292A (es) | 2007-07-04 |
Family
ID=35839637
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2007001292A MX2007001292A (es) | 2004-08-03 | 2005-08-03 | Metodo para modular la expresion genica al alterar el contendido de cpg. |
Country Status (14)
Country | Link |
---|---|
US (4) | US8859275B2 (es) |
EP (1) | EP1776460B8 (es) |
JP (1) | JP4550115B2 (es) |
KR (1) | KR101222628B1 (es) |
AT (1) | ATE453716T1 (es) |
AU (1) | AU2005270430B2 (es) |
BR (1) | BRPI0513081A (es) |
CA (1) | CA2575490A1 (es) |
DE (1) | DE502005008794D1 (es) |
DK (1) | DK1776460T3 (es) |
HK (1) | HK1100089A1 (es) |
IL (1) | IL180786A (es) |
MX (1) | MX2007001292A (es) |
WO (1) | WO2006015789A2 (es) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005270430B2 (en) * | 2004-08-03 | 2008-06-12 | Geneart Ag | Method for modulating gene expression by modifying the CpG content |
NZ569541A (en) | 2006-01-13 | 2012-05-25 | Us Gov Health & Human Serv | Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells |
GB0606190D0 (en) | 2006-03-28 | 2006-05-10 | Isis Innovation | Construct |
US20100092435A1 (en) | 2006-12-07 | 2010-04-15 | Emmanuel Jacques Henri Joseph Wiertz | Use of a varicellovirus tap-inhibitor for the induction of tumor-or virus-specific immunity against teipp |
CN101861168B (zh) | 2007-05-07 | 2014-07-02 | 米迪缪尼有限公司 | 抗-icos抗体及其在***、移植和自身免疫病中的应用 |
WO2009014445A2 (en) | 2007-07-26 | 2009-01-29 | Amsterdam Molecular Therapeutics B.V. | Baculoviral vectors comprising repeated coding sequences with differential codon biases |
EP2019134A1 (en) * | 2007-07-26 | 2009-01-28 | Vision 7 GmbH | Gene therapy of chronic granulomatous disease |
ES2429142T3 (es) | 2009-01-30 | 2013-11-13 | Uniqure Ip B.V. | Agentes terapéuticos de alanina-glioxilato aminotransferasa |
WO2011100369A2 (en) * | 2010-02-09 | 2011-08-18 | The Trustees Of Columbia University In The City Of New York | Methods for altering polypeptide expression and solubility |
CA2819181C (en) | 2010-11-29 | 2020-03-10 | Dako Denmark A/S | Methods and systems for analyzing images of specimens processed by a programmable quantitative assay |
DE102010056289A1 (de) | 2010-12-24 | 2012-06-28 | Geneart Ag | Verfahren zur Herstellung von Leseraster-korrekten Fragment-Bibliotheken |
CN103907117B (zh) | 2011-09-01 | 2019-03-29 | 基因组编译器公司 | 用于多核苷酸构建体设计的***和方法 |
LT2768607T (lt) | 2011-09-26 | 2021-12-27 | Thermo Fisher Scientific Geneart Gmbh | Daugiašulininė plokštelė didelio efektyvumo, mažo tūrio nukleorūgščių sintezei atlikti |
WO2014153188A2 (en) | 2013-03-14 | 2014-09-25 | Life Technologies Corporation | High efficiency, small volume nucleic acid synthesis |
WO2013152220A2 (en) | 2012-04-04 | 2013-10-10 | Life Technologies Corporation | Tal-effector assembly platform, customized services, kits and assays |
PL3030682T3 (pl) | 2013-08-05 | 2020-11-16 | Twist Bioscience Corporation | Biblioteki genowe syntezowane de novo |
EP4043032A1 (en) * | 2013-08-21 | 2022-08-17 | CureVac AG | Rabies vaccine |
PE20160224A1 (es) * | 2013-08-21 | 2016-05-14 | Curevac Ag | Composicion y vacuna para tratar cancer de pulmon |
AU2014310934B2 (en) | 2013-08-21 | 2019-09-12 | CureVac SE | Respiratory syncytial virus (RSV) vaccine |
EP3035955B1 (en) * | 2013-08-21 | 2019-09-11 | CureVac AG | Composition and vaccine for treating lung cancer |
AU2014310931B2 (en) | 2013-08-21 | 2019-12-19 | CureVac SE | Rabies vaccine |
EP3586871A3 (en) * | 2013-08-21 | 2020-03-11 | CureVac AG | Respiratory syncytial virus (rsv) vaccine |
KR20160043103A (ko) * | 2013-08-21 | 2016-04-20 | 큐어백 아게 | 전립선암 치료를 위한 조성물 및 백신 |
WO2016077123A1 (en) | 2014-11-10 | 2016-05-19 | Moderna Therapeutics, Inc. | Multiparametric nucleic acid optimization |
GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
CN107532129B (zh) | 2014-12-09 | 2022-09-13 | 生命技术公司 | 高效小体积核酸合成 |
WO2016126882A1 (en) | 2015-02-04 | 2016-08-11 | Twist Bioscience Corporation | Methods and devices for de novo oligonucleic acid assembly |
US9981239B2 (en) | 2015-04-21 | 2018-05-29 | Twist Bioscience Corporation | Devices and methods for oligonucleic acid library synthesis |
DK3294885T3 (da) | 2015-05-08 | 2020-08-10 | Curevac Real Estate Gmbh | Fremgangsmåde til at fremstille rna |
WO2016193206A1 (en) | 2015-05-29 | 2016-12-08 | Curevac Ag | A method for producing and purifying rna, comprising at least one step of tangential flow filtration |
KR20180050411A (ko) | 2015-09-18 | 2018-05-14 | 트위스트 바이오사이언스 코포레이션 | 올리고핵산 변이체 라이브러리 및 그의 합성 |
CN108698012A (zh) | 2015-09-22 | 2018-10-23 | 特韦斯特生物科学公司 | 用于核酸合成的柔性基底 |
US9895673B2 (en) | 2015-12-01 | 2018-02-20 | Twist Bioscience Corporation | Functionalized surfaces and preparation thereof |
GB2568444A (en) | 2016-08-22 | 2019-05-15 | Twist Bioscience Corp | De novo synthesized nucleic acid libraries |
US10417457B2 (en) | 2016-09-21 | 2019-09-17 | Twist Bioscience Corporation | Nucleic acid based data storage |
US20190263906A1 (en) | 2016-11-10 | 2019-08-29 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Immune modulators for reducing immune-resistance in melanoma and other proliferative diseases |
CN110366613A (zh) | 2016-12-16 | 2019-10-22 | 特韦斯特生物科学公司 | 免疫突触的变体文库及其合成 |
SG11201907713WA (en) | 2017-02-22 | 2019-09-27 | Twist Bioscience Corp | Nucleic acid based data storage |
CN110913865A (zh) | 2017-03-15 | 2020-03-24 | 特韦斯特生物科学公司 | 免疫突触的变体文库及其合成 |
WO2018195339A1 (en) | 2017-04-19 | 2018-10-25 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
WO2018231872A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
WO2018231864A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
JP2020536504A (ja) | 2017-09-11 | 2020-12-17 | ツイスト バイオサイエンス コーポレーション | Gpcr結合タンパク質およびその合成 |
JP7066840B2 (ja) | 2017-10-20 | 2022-05-13 | ツイスト バイオサイエンス コーポレーション | ポリヌクレオチド合成のための加熱されたナノウェル |
JP7191448B2 (ja) | 2018-01-04 | 2022-12-19 | ツイスト バイオサイエンス コーポレーション | Dnaベースのデジタル情報ストレージ |
EP3508499A1 (en) | 2018-01-08 | 2019-07-10 | iOmx Therapeutics AG | Antibodies targeting, and other modulators of, an immunoglobulin gene associated with resistance against anti-tumour immune responses, and uses thereof |
EP3768858A1 (en) | 2018-03-19 | 2021-01-27 | Modernatx, Inc. | Assembly and error reduction of synthetic genes from oligonucleotides |
CA3100739A1 (en) | 2018-05-18 | 2019-11-21 | Twist Bioscience Corporation | Polynucleotides, reagents, and methods for nucleic acid hybridization |
US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
CN113766930A (zh) | 2019-02-26 | 2021-12-07 | 特韦斯特生物科学公司 | Glp1受体的变异核酸文库 |
JP2022522668A (ja) | 2019-02-26 | 2022-04-20 | ツイスト バイオサイエンス コーポレーション | 抗体を最適化するための変異体核酸ライブラリ |
CA3144644A1 (en) | 2019-06-21 | 2020-12-24 | Twist Bioscience Corporation | Barcode-based nucleic acid sequence assembly |
AU2020300519A1 (en) * | 2019-06-30 | 2022-02-24 | John Fraser Wright | Recombinant AAV vectors with altered immunogencity and methods of making the same |
JP2022538688A (ja) | 2019-07-05 | 2022-09-05 | イオックス セラピューティクス アーゲー | IGSF11(VSIG3)のIgC2に結合する抗体及びその使用 |
EP3822288A1 (en) | 2019-11-18 | 2021-05-19 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof |
EP4175668A1 (en) | 2020-07-06 | 2023-05-10 | iOmx Therapeutics AG | Antibodies binding igv of igsf11 (vsig3) and uses thereof |
CA3173151A1 (en) | 2020-11-03 | 2022-05-12 | Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | Target-cell restricted, costimulatory, bispecific and bivalent anti-cd28 antibodies |
EP3992205A1 (en) | 2020-11-03 | 2022-05-04 | Rheinische Friedrich-Wilhelms-Universität Bonn | Sars coronavirus-2 spike protein binding compounds |
WO2022106205A1 (en) | 2020-11-18 | 2022-05-27 | Rheinische Friedrich-Wilhelms-Universität Bonn | Corona virus spike protein binding compounds |
EP4301402A1 (en) | 2021-03-03 | 2024-01-10 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Bispecific antibodies enhancing cell mediated immune responses |
WO2023018854A2 (en) * | 2021-08-11 | 2023-02-16 | Solid Biosciences Inc. | Treatment of muscular dystrophy |
WO2024067780A1 (zh) * | 2022-09-30 | 2024-04-04 | 南京金斯瑞生物科技有限公司 | 一种降低外源核酸免疫原性的密码子优化 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050131267A1 (en) * | 1995-06-07 | 2005-06-16 | Talmadge Karen D. | System and method for delivering a therapeutic agent for bone disease |
WO1998052581A1 (en) * | 1997-05-20 | 1998-11-26 | Ottawa Civic Hospital Loeb Research Institute | Vectors and methods for immunization or therapeutic protocols |
EP1700603A3 (en) * | 1999-09-25 | 2007-06-13 | Coley Pharmaceutical GmbH | Immunostimulatory nucleic acids |
DE60117761T2 (de) | 2000-03-15 | 2006-08-31 | Prolume, Ltd. | Luciferase, Fluoreszenzproteine, für Luciferase und Fluoreszenzproteine Kodierend Nukleinsäure und ihre Verwendung in der Diagnose, Hoch-Durchsatz Screeningsverfahren |
DE60026199T2 (de) * | 2000-05-18 | 2006-11-23 | Geneart Ag | Synthetische Gene für gagpol und deren Verwendungen |
US6919204B2 (en) * | 2000-09-29 | 2005-07-19 | Sangamo Biosciences, Inc. | Modulation of gene expression using localization domains |
DE10053781B4 (de) | 2000-10-30 | 2008-07-03 | Geneart Ag | Kernexportreportersystem |
CA2443275C (en) | 2001-04-05 | 2013-02-05 | Ml Laboratories Plc | Improved gene expression |
WO2002099105A2 (en) | 2001-06-05 | 2002-12-12 | Cellectis | Methods for modifying the cpg content of polynucleotides |
US7569553B2 (en) * | 2002-07-03 | 2009-08-04 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7576066B2 (en) * | 2002-07-03 | 2009-08-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7605138B2 (en) * | 2002-07-03 | 2009-10-20 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
AR040575A1 (es) * | 2002-07-16 | 2005-04-13 | Advisys Inc | Plasmidos sinteticos optimizados en codones de expresion en mamiferos |
DE10260805A1 (de) * | 2002-12-23 | 2004-07-22 | Geneart Gmbh | Verfahren und Vorrichtung zum Optimieren einer Nucleotidsequenz zur Expression eines Proteins |
EP1745261B1 (en) | 2004-05-12 | 2012-11-14 | Northrop Grumman Systems Corporation | System and method for aligning multiple navigation components |
DE102004037611B4 (de) * | 2004-08-03 | 2013-10-02 | Geneart Ag | Induzierbare Genexpression |
AU2005270430B2 (en) * | 2004-08-03 | 2008-06-12 | Geneart Ag | Method for modulating gene expression by modifying the CpG content |
DE102007052344B3 (de) * | 2007-11-02 | 2009-03-12 | Geneart Ag | Selektion kodierender Nukleinsäure-Konstrukte auf Abwesenheit von Frameshift-Mutationen |
US20160040163A1 (en) * | 2013-03-15 | 2016-02-11 | Pronai Therapeutics, Inc. | Dnai for the modulation of genes |
-
2005
- 2005-08-03 AU AU2005270430A patent/AU2005270430B2/en not_active Ceased
- 2005-08-03 EP EP20050768791 patent/EP1776460B8/de active Active
- 2005-08-03 DK DK05768791T patent/DK1776460T3/da active
- 2005-08-03 KR KR1020077004967A patent/KR101222628B1/ko active IP Right Grant
- 2005-08-03 CA CA 2575490 patent/CA2575490A1/en not_active Abandoned
- 2005-08-03 MX MX2007001292A patent/MX2007001292A/es not_active Application Discontinuation
- 2005-08-03 DE DE200550008794 patent/DE502005008794D1/de active Active
- 2005-08-03 JP JP2007524277A patent/JP4550115B2/ja active Active
- 2005-08-03 AT AT05768791T patent/ATE453716T1/de active
- 2005-08-03 BR BRPI0513081-6A patent/BRPI0513081A/pt not_active IP Right Cessation
- 2005-08-03 WO PCT/EP2005/008423 patent/WO2006015789A2/de active Application Filing
- 2005-08-03 US US11/659,315 patent/US8859275B2/en active Active
-
2007
- 2007-01-18 IL IL180786A patent/IL180786A/en active IP Right Grant
- 2007-07-23 HK HK07107945A patent/HK1100089A1/xx not_active IP Right Cessation
-
2014
- 2014-09-10 US US14/483,142 patent/US10273486B2/en active Active
-
2019
- 2019-03-11 US US16/298,715 patent/US20190270999A1/en not_active Abandoned
-
2020
- 2020-10-26 US US17/080,333 patent/US20210155940A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
DE502005008794D1 (de) | 2010-02-11 |
CA2575490A1 (en) | 2006-02-16 |
US8859275B2 (en) | 2014-10-14 |
WO2006015789A3 (de) | 2006-06-01 |
US10273486B2 (en) | 2019-04-30 |
KR101222628B1 (ko) | 2013-01-16 |
EP1776460A2 (de) | 2007-04-25 |
AU2005270430A1 (en) | 2006-02-16 |
JP2008507986A (ja) | 2008-03-21 |
ATE453716T1 (de) | 2010-01-15 |
KR20070041605A (ko) | 2007-04-18 |
US20210155940A1 (en) | 2021-05-27 |
US20190270999A1 (en) | 2019-09-05 |
WO2006015789A2 (de) | 2006-02-16 |
JP4550115B2 (ja) | 2010-09-22 |
IL180786A0 (en) | 2007-06-03 |
IL180786A (en) | 2013-08-29 |
AU2005270430B2 (en) | 2008-06-12 |
HK1100089A1 (en) | 2007-09-07 |
EP1776460B8 (de) | 2014-02-26 |
BRPI0513081A (pt) | 2008-04-22 |
US20090324546A1 (en) | 2009-12-31 |
US20150104832A1 (en) | 2015-04-16 |
EP1776460B1 (de) | 2009-12-30 |
DK1776460T3 (da) | 2010-04-12 |
EP1776460B2 (de) | 2013-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1100089A1 (en) | Method for modulating gene expression by modifying the cpg content | |
WO2003014307A3 (en) | Antisense modulation of apolipoprotein(a) expression | |
EP1569695A4 (en) | ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION | |
WO2004005460A3 (en) | Antisense modulation of hmg-coa reductase expression | |
WO2003011887A3 (en) | Antisense modulation of apolipoprotein b expression | |
WO2002036743A3 (en) | Antisense modulation of calreticulin expression | |
AU2001290706A1 (en) | Antisense modulation of clusterin expression | |
WO2003097662A8 (en) | Antisense modulation of apolipoprotein b expression | |
MX2007006610A (es) | Metodo para simplificar acidos nucleicos microbianos por modificacion quimica de citosinas. | |
EP1248794A4 (en) | ANTISENSE MODULATION OF SMAD7 PROTEIN EXPRESSION | |
WO2003046132A3 (en) | Antisense modulation of myd88 expression | |
WO2003053341A3 (en) | Antisense modulation of ship-1 expression | |
WO2001083513A3 (en) | Antisense modulation of inhibitor of dna binding-1 expression | |
WO2002095053A3 (en) | Antisense modulation of src-c expression | |
WO2002050248A3 (en) | Antisense modulation of hepsin expression | |
WO2004010956A3 (en) | Antisense modulation of lar expression | |
WO2003052062A3 (en) | Antisense modulation of cd36l1 expression | |
WO2003027229A3 (en) | Antisense modulation of rip2 expression | |
WO2004003201A3 (en) | Antisense modulation of lrh1 expression | |
WO2003106645A3 (en) | ANTISENSE MODULATION OF SMRT COREPRESSOR EXPRESSION | |
WO2002041836A3 (en) | Antisense modulation of src-1 expression | |
WO2003031576A3 (en) | Antisense modulation of inhibitor-kappa b kinase-gamma expression | |
EP1414999A4 (en) | ANTISENSE MODULATION OF EXPRESSION OF ACYL-COENZYME-A-CHOLESTERIN ACYLTRANSFERASE 1 | |
WO2003050247A3 (en) | Antisense modulation of mhc class ii transactivator expression | |
WO2004015126A3 (en) | Antisense modulation of edg1 expression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |